[Show abstract] [Hide abstract]
ABSTRACT: Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable profile for inhaled dosing.
Bioorganic & medicinal chemistry letters 05/2009; 19(17):5261-5. DOI:10.1016/j.bmcl.2009.04.012 · 2.33 Impact Factor